Oruka Therapeutics, Inc., a biotechnology company specializing in novel biologics for chronic skin diseases, has announced the commencement of its first clinical trial for ORKA-002. This trial involves dosing healthy volunteers with ORKA-002, a half-life extended monoclonal antibody targeting IL-17A/F, which is administered subcutaneously. The Phase 1 trial is designed as a double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 across three subcutaneous dose cohorts in approximately 24 participants. Interim data from this study is expected by the end of 2025. Oruka aims to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026, with a focus on assessing multiple dose levels and regimens.